Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13

Journal of the Neurological Sciences

Volumn 325, Issue 1-2, 2013, Pages 79-85

  Kvarnstrom M ^a   Ydrefors, J ^a,b   Ekerfelt, C ^a   Vrethem, M ^a,b   Ernerudh, J ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Department of Clinical Immunology and Transfusion Medicine   (Sweden)

Author keywords

Cytokines; IL 10; IL 17; IL 4; Interferon ; Multiple sclerosis; Responder

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; MITOGENIC AGENT; MYELIN;

ADULT; AGED; ARTICLE; CELLULAR SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-17; INTERLEUKIN-4; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84872914335     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.12.001     Document Type: Article

References (38)

1. H.S. Panitch, R.L. Hirsch, A.S. Haley, and K.P. Johnson Exacerbations of multiple sclerosis in patients treated with gamma interferon Lancet 18 1987 893 895
2. V.W. Yong, S. Chabot, O. Stuve, and G. Williams Interferon beta in the treatment of multiple sclerosis: mechanisms of action Neurology 51 1998 682 689 (Pubitemid 28449243)
3. F. Jadidi-Niaragh, and A. Mirshafiey Th17 cell, the new player of neuroinflammatory process in multiple sclerosis Scand J Immunol 74 2011 1 13
4. A.L. Zozulya, and H. Wiendl The role of regulatory T cells in multiple sclerosis Nat Clin Pract Neurol 4 2008 384 398 (Pubitemid 352003290)
5. M. Akdis, S. Burgler, R. Crameri, T. Eiwegger, H. Fujita, and E. Gomez Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases J Allergy Clin Immunol 127 2011 701 721
6. V. Viglietta, C. Baecher-Allan, H.L. Weiner, and D.A. Hafler Loss of functional suppression by CD4 + CD25 + regulatory T cells in patients with multiple sclerosis J Exp Med 199 2004 971 979 (Pubitemid 38481088)
7. M. Edström, J. Mellergård, J. Mjösberg, M. Jenmalm, M. Vrethem, and R. Press Transcriptional characteristics of CD4 + T cells in multiple sclerosis: relative lack of suppressive populations in blood Mult Scler 17 2011 57 66
8. B.C. Kieseier The mechanism of action of interferon-β in relapsing multiple sclerosis CNS Drugs 1 2011 491 502
9. J. Río, C. Nos, M. Tintoré, N. Téllez, I. Galán, and R. Pelayo Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients Ann Neurol 59 2006 344 352 (Pubitemid 43202488)
10. J. Hong, and G.J. Hutton Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis J Interferon Cytokine Res 30 2010 751 757
11. M. Chen, G. Chen, H. Nie, X. Zhang, X. Niu, and Y.C. Zang Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4 + T Cells in MS Eur J Immunol 39 2009 2525 2536
12. L. Durelli, L. Conti, M. Clerico, D. Boselli, G. Contessa, and P. Ripellino T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta Ann Neurol 65 2009 499 509
13. V.S. Ramgolam, Y. Sha, J. Jin, X. Zhang, and S. Markovic-Plese IFN-beta inhibits human Th17 cell differentiation J Immunol 183 2009 5418 5427
14. C.M. Sweeney, R. Lonergan, S.A. Basdeo, K. Kinsella, L.S. Dungan, and S.C. Higgins IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells Brain Behav Immun 25 2011 1170 1181
15. R.C. Axtell, C. Raman, and L. Steinman Interferon-β exacerbates Th17-mediated inflammatory disease Trends Immunol 32 2011 272 277
16. R.C. Axtell, B.A. de Jong, K. Boniface, L.F. van der Voort, R. Bhat, and P. De Sarno T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis Nat Med 16 2010 406 412
17. S. Dhib-Jalbut, S. Sumandeep, R. Valenzuela, K. Ito, P. Patel, and M. Rametta Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study J Neuroimmunol Sep 18 2012 10.1016/j.jneuroim.2012.08.012 [pii: S0165-5728(12)00268-8, Epub ahead of print]
18. S.E. Bushnell, Z. Zhao, C.C. Stebbins, D. Cadavid, A.M. Buko, and E.T. Whalley Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS Neurology 79 2012 531 537
19. W.I. McDonald, A. Compston, G. Edan, D. Goodkin, H.P. Hartung, and F.D. Lublin Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Ann Neurol 50 2001 121 127
20. T. Olsson, W.W. Zhi, B. Höjeberg, V. Kostulas, Y.P. Jiang, and G. Anderson Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma J Clin Invest 86 1990 981 985 (Pubitemid 20327391)
21. J. Sun, H. Link, T. Olsson, B.G. Xiao, G. Andersson, and H.P. Ekre T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis J Immunol 146 1991 1490 1495
22. E. Wallström, M. Khademi, M. Andersson, R. Weissert, C. Linington, and T. Olsson Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis Eur J Immunol 28 1998 3329 3335 (Pubitemid 28470279)
23. A. Bøyum Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g Scand J Clin Lab Invest Suppl 97 1968 77 89
24. C. Ekerfelt, L. Matthiesen, G. Berg, and J. Ernerudh Paternal leukocytes selectively increase secretion of IL-4 in peripheral blood during normal pregnancies: demonstrated by a novel one-way MLC measuring cytokine secretion Am J Reprod Immunol 38 1997 320 326 (Pubitemid 27427394)
25. A. Jansson, J. Ernerudh, M. Kvarnström, C. Ekerfelt, and M. Vrethem Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients Mult Scler 9 2003 440 445 (Pubitemid 37287720)
26. M.C. Jenmalm, J. Van Snick, F. Cormont, and B. Salman Allergen-induced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children Clin Exp Allergy 31 2001 1528 1535 (Pubitemid 32939459)
27. D.J. Huss, R.C. Winger, G.M. Cox, M. Guerau-de-Arellano, Y. Yang, and M.K. Racke TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE Eur J Immunol 41 2011 2987 2996
28. R.A. Rudick, R.M. Ransohoff, J.C. Lee, R. Peppler, M. Yu, and P.M. Mathisen In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis Neurology 50 1998 1294 1300 (Pubitemid 28240342)
29. V. Özenci, M. Kouwenhoven, Y.M. Huang, B. Xiao, P. Kivisäkk, and S. Fredrikson Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment Scand J Immunol 49 1999 554 561 (Pubitemid 29243129)
30. A.A. Byrnes, J.C. McArthur, and C.L. Karp Interferon-therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production Ann Neurol 51 2002 165 174 (Pubitemid 34111438)
31. J.J. Graber, D. Ford, M. Zhan, G. Francis, H. Panitch, and S. Dhib-Jalbut Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response J Neuroimmunol 185 2007 168 174 (Pubitemid 46497443)
32. D.J. DiLillo, T. Matsushita, and T.F. Tedder B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer Ann N Y Acad Sci 1183 2010 38 57
33. M.H. Rep, H.M. Schrijver, T. van Lopik, R.Q. Hintzen, M.T. Roos, and H.J. Ader Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients J Neuroimmunol 96 1999 92 100 (Pubitemid 29179749)
34. M. Schluep, G. van Melle, H. Henry, C. Städler, B. Roth-Wicky, and P.J. Magistretti Assessing multiple sclerosis activity: is the in vitro production of tumor necrosis factor-alpha, interleukins 2, 6, 4, and 10, and immunoglobulin G of value? J Neurol 246 1999 1041 1050
35. M. Andersson, M. Khademi, E. Wallström, and T. Olsson Cytokine profile in interferon-beta treated multiple sclerosis patients: reduction of interleukin-10 mRNA expressing cells in peripheral blood Eur J Neurol 4 1997 567 571 (Pubitemid 28005941)
36. R. Furlan, A. Bergami, R. Lang, E. Brambilla, D. Franciotta, and V. Martinelli Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4 J Neuroimmunol 111 2000 86 92
37. M. Khademi, E. Wallström, M. Andersson, F. Piehl, R. Di Marco, and T. Olsson Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis J Neuroimmunol 103 2000 202 210 (Pubitemid 30079733)
38. S.A. Brod, G.D. Marshall Jr., E.M. Henninger, S. Sriram, M. Khan, and J.S. Wolinsky Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis Neurology 46 1996 1633 1638